Analysing the SLC25A32 protein expression level data from the CPTAC database in the UALCAN platform revealed that SLC25A32 protein expression increased over SLC25A32 in OV, UCEC, lung cancer, HNSC, and liver cancer and decreased over SLC25A32 in PAAD and glioblastoma (Figures 4(a) and 4(d)). Here, SLC25A32 is linked to lung carcinoma.